A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Duska, LR; Brown, J; Jelovac, D; Moore, KN; McGuire, WP; Darus, C; Barroilhet, LM; Secord, AA

Published Date

  • May 20, 2017

Published In

Volume / Issue

  • 35 / 15_suppl

Start / End Page

  • 5532 - 5532

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2017.35.15_suppl.5532